UNSPSC 51182426: Cinacalcet

This classification denotes a malignancy-associated hypercalcemia inhibitor with the molecular formula C22H22F3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UAZ6V7728S, chemically known as 1-naphthalenemethanamine, a-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (ar)- but generally known as cinacalcet, which bears US NIH Compound Identifier 156419. European Medicines Agency schedules Cinacalcet in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20068.

UNSPSC 51182426 Cinacalcet is a Commodity code for a specific pharmaceutical product used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. State and local governments procure this medication primarily through Medicaid agencies, state health departments, county health systems, and public hospital networks that serve low-income and uninsured populations. The drug is dispensed as part of formulary-managed prescription benefit programs and institutional pharmacy operations at dialysis centers operated or subsidized by state and local entities. Procurement occurs through standing purchase agreements, cooperative pharmaceutical purchasing vehicles, and competitive bid cycles managed by state pharmacy benefit managers or group purchasing organizations that consolidate demand across multiple jurisdictions.

The source provided contains no recent state or local contract opportunities tagged to this code. Without posted solicitations identifying the issuing bodies, geographic regions, notice types, or response dates, no representative opportunities can be named. Given that cinacalcet is a specialized therapeutic agent dispensed through established formulary channels rather than a general commodity frequently put to bid, activity under this Commodity code may be episodic or conducted through pre-established framework agreements rather than open competitive solicitations.